Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

BACKGROUND: Dyslipidemia is a major risk factor for cardiovascular events. The prognostic importance of lipoproteins in patients with atrial fibrillation is not well understood. We aimed to explore the association between apolipoprotein A1 (ApoA1) and B (ApoB) and cardiovascular events in patients w...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Am Heart Assoc
Main Authors: Pol, Tymon, Held, Claes, Westerbergh, Johan, Lindbäck, Johan, Alexander, John H., Alings, Marco, Erol, Cetin, Goto, Shinya, Halvorsen, Sigrun, Huber, Kurt, Hanna, Michael, Lopes, Renato D., Ruzyllo, Witold, Granger, Christopher B., Hijazi, Ziad
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2018
主題:
Original Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5850246/
https://ncbi.nlm.nih.gov/pubmed/29419390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.117.007444
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍